Phase 2

Longer than expected PFS for murlentamab when combined with FTD/TPI, particularly in patients with medium/high AMHRII expression, along with immune cascade activation in the tumor micro-environment

Da Volterra, a clinical-stage biopharmaceutical company developing new therapeutics to protect the intestinal microbiota, announced the completion of patient recruitment for its Phase 2 trial ‘SHIELD’ evaluating DAV132 in patients receiving antibiotics.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines, presented the research data on the treatment of relapsed or refractory extranodal NK/T cell lymphoma with sintilimab, co-developed with Eli Lilly and Company and key data from six other clinical studies were presented at the 55th Annual Meeting of the American Society of Clinical Oncology by oral presentation and posters.

Even with a holiday week, July 4, there were a number of clinical trial reports. Here’s a look.

Trial Designed to Test Camsirubicin Against Doxorubicin as First-Line Therapy

Companies from across the globe provide information on agreements and pipeline updates.

Pancreatic cancer is a particularly difficult cancer to treat, and although there have been advances in treatment, it is still an extremely deadly disease. Here’s a look at some recent news concerning pancreatic cancer.

Dicerna Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced it has submitted a Clinical Trial Authorization (CTA) application to the Swedish Medical Products Agency (MPA).

Now that Novartis has a competing therapy on the market for spinal muscular atrophy (SMA), Biogen is eager to show why it thinks its Spinraza (nusinersen) is superior.

Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.